| Literature DB >> 30926635 |
Xihua Cao1, Liqun Chen2, Xiaohui Chen2, Xuhuang Tu2, Gulimiran Alitongbieke2, Zebin Xia1, Xiaotong Li2, Ziwen Chen2, Meimei Yin, Dan Xu2, Shangjie Guo2, Zongxi Li2, Xindao Zhang2, Dingyu Xu2, Meichun Gao2, Jie Liu2, Zhiping Zeng2, Hu Zhou2, Ying Su3, Xiao-Kun Zhang4,1.
Abstract
Nur77 (also called TR3 or NGFI-B), an orphan member of the nuclear receptor superfamily, induces apoptosis by translocating to mitochondria where it interacts with Bcl-2 to convert Bcl-2 from an antiapoptotic to a pro-apoptotic molecule. Nur77 posttranslational modification such as phosphorylation has been shown to induce Nur77 translocation from the nucleus to mitochondria. However, small molecules that can bind directly to Nur77 to trigger its mitochondrial localization and Bcl-2 interaction remain to be explored. Here, we report our identification and characterization of DIM-C-pPhCF3 +MeSO3 - (BI1071), an oxidized product derived from indole-3-carbinol metabolite, as a modulator of the Nur77-Bcl-2 apoptotic pathway. BI1071 binds Nur77 with high affinity, promotes Nur77 mitochondrial targeting and interaction with Bcl-2, and effectively induces apoptosis of cancer cells in a Nur77- and Bcl-2-dependent manner. Studies with animal model showed that BI1071 potently inhibited the growth of tumor cells in animals through its induction of apoptosis. Our results identify BI1071 as a novel Nur77-binding modulator of the Nur77-Bcl-2 apoptotic pathway, which may serve as a promising lead for treating cancers with overexpression of Bcl-2. ©2019 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30926635 PMCID: PMC6527444 DOI: 10.1158/1535-7163.MCT-18-0918
Source DB: PubMed Journal: Mol Cancer Ther ISSN: 1535-7163 Impact factor: 6.261